Research Output per year
Personal profile
Biography
Dr. Willem (Joost) Lesterhuis is an NHMRC RD Wright Research Fellow with the School of Biomedical Sciences and the National Centre for Asbestos Related Diseases at the University of Western Australia. He has a background as a dual-trained medical oncologist and basic researcher in tumour immunology and cancer biology.
His research focuses on identifying new effective treatment combinations in cancer, in particular in mesothelioma, and focusing on immunotherapy. Using network analysis of gene expression data from tumours in mouse models and patient samples, his research aims to identify predictive biomarkers for clinical efficacy of immuno-oncology drugs, as well as new context-specific targets for pharmacological intervention and novel combination treatments.
His research combines several lines of science; systems biology, network science, cancer biology, pharmacology/drug discovery, immunology and translational oncology.
Research
Current research projects include:
1- Combining chemotherapy and immunotherapy to treat cancer, in particular mesothelioma and lung cancer.
2- Unravelling the cellular and molecular processes that govern successful immunotherapy-induced cancer regression, using systems biology approaches.
3- Identification of the molecular processes that drive mesothelioma invasion using network analysis of high-dimensional molecular data from mouse models and patient samples.
1- Combining chemotherapy and immunotherapy to treat cancer, in particular mesothelioma and lung cancer.
2- Unravelling the cellular and molecular processes that govern successful immunotherapy-induced cancer regression, using systems biology approaches.
3- Identification of the molecular processes that drive mesothelioma invasion using network analysis of high-dimensional molecular data from mouse models and patient samples.
Fingerprint Dive into the research topics where Willem Lesterhuis is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 23 Similar Profiles
Neoplasms
Medicine & Life Sciences
Mesothelioma
Medicine & Life Sciences
Immunotherapy
Medicine & Life Sciences
Drug Therapy
Medicine & Life Sciences
gemcitabine
Medicine & Life Sciences
Cross-Priming
Medicine & Life Sciences
Vaccination
Medicine & Life Sciences
Dendritic Cells
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 2008 2019
Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment
Aston, W. J., Hope, D. E., Cook, A. M., Boon, L., Dick, I., Nowak, A. K., Lake, R. A. & Lesterhuis, W. J., Jul 2019, In : OncoImmunology. 8 p.Research output: Contribution to journal › Article
Open Access
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
Zemek, R., de Jong, E., Chin, M., Schuster, I., Fear, V., Casey, T., Forbes, C., Dart, S., Leslie, C., Zaitouny, A., Small, M., Boon, L., Forrest, A. R. R., O Muiri, D., Degli-Esposti, M., Millward, M., Nowak, A., Lassmann, T., Bosco, A., Lake, R. & 1 others, 17 Jul 2019, In : Science Translational Medicine. 11, 501, 14 p., eaav7816.Research output: Contribution to journal › Article
Open Access
File
STAT1 Transcription Factor
Tumor Microenvironment
Neoplasms
Toll-Like Receptor 3
Transcriptome
Combination immune checkpoint blockade as an effective therapy for mesothelioma
Fear, V., Tilsed, C. M., Chee, H. E. J., Forbes, C., Casey, T., Solin, J., Lansley, S., Lesterhuis, W., Dick, I., Nowak, A., Robinson, B., Lake, R. & Fisher, S., 30 Jul 2018, In : Oncolmmunology. 14 p., e1494111.Research output: Contribution to journal › Article
Open Access
Mesothelioma
Neoplasms
Therapeutics
Asbestos
Regulatory T-Lymphocytes
Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors
Chee, J., Watson, M. W., Chopra, A., Nguyen, B., Cook, A. M., Creaney, J., Lesterhuis, W. J., Robinson, B. W., Gary Lee, Y. C., Nowak, A. K., Lake, R. A. & McDonnell, A. M., 5 Dec 2018, In : BMC Research Notes. 11, 1, 6 p., 864.Research output: Contribution to journal › Article
Open Access
Lymphocytes
Mesothelioma
Pleural Effusion
Tumors
Blood
12
Citations
(Scopus)
A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice
Aston, W. J., Hope, D. E., Nowak, A. K., Robinson, B. W., Lake, R. A. & Lesterhuis, W. J., 16 Oct 2017, In : BMC Cancer. 17, 1, 684.Research output: Contribution to journal › Article
Open Access
Maximum Tolerated Dose
Drug Therapy
Inbred C57BL Mouse
Dexamethasone
Weight Loss
Projects 2014 2021
2019 Sarcoma Research Grant - Johanna Sewell - Local peri-operative immunotherapy for soft tissue sarcoma
Lesterhuis, W., Swaminatha Iyer, K. & Zemek, R.
Australasian Sarcoma Study Group ASSG
1/01/19 → 31/12/19
Project: Research
DREAM predictive biomarkers
Nowak, A., Cook, A. & Lesterhuis, W.
Mesothelioma Applied Research Foundation
1/01/19 → 31/12/20
Project: Research
Project Grant - Studying translational biomarkers from a positive clinical trial of chemoimmunotherapy
Nowak, A., Lesterhuis, W., Cook, A., Lassmann, T., McDonnell, A. & Yip, S.
1/01/19 → 31/12/19
Project: Research
The MexTAg Collaborative Cross: understanding genetic modifiers in mesothelioma
Lake, R., Fisher, S., Morahan, G., Ram, R., Lesterhuis, W. & Nowak, A.
15/07/18 → 14/07/20
Project: Research